ICON plc (ICLR) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Wait for pullback to $107.73. At $111.51 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $107.73 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Thin upside margin: 5.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5).
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of... Read more
Wait for pullback to $107.73. At $111.51 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $107.73 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Thin upside margin: 5.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5). Chart setup: RSI 43 mid-range, Bollinger mid-band. Earnings in 0 days. Wait until post-earnings. Score 4.5/10, moderate confidence.
Passes 4/8 gates (clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 0d<=7d. Suitability: moderate.
Recent Developments — ICON plc
Latest news
- ICLR Stock Holds Support As Traders Watch Next Move - StocksToTrade — StocksToTrade neutral
- ICLR Stock Climbs As Support Holds And Value Case Builds - timothysykes.com — timothysykes.com positive
- ICON Public Limited (ICLR) Shares Surge 13% Following Investigat - GuruFocus — GuruFocus positive
- ICLR Stock Holds Support As Traders Watch Next Break - StocksToTrade — StocksToTrade neutral
- ICON (ICLR) Completes Audit Investigation and Plans Financial Re - GuruFocus — GuruFocus negative
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $107.73. At $111.51 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $107.73 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Thin upside margin: 5.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5). Chart setup: RSI 43 mid-range, Bollinger mid-band. Earnings in 0 days. Wait until post-earnings. Target $119.34 (+7.0%), stop $95.19 (−17.1%), Setup A.R:R 1.6:1. Score 4.5/10, moderate confidence.
Take-profit target: $119.34 (+11.4% upside). Target $119.34 (+7.0%), stop $95.19 (−17.1%), Setup A.R:R 1.6:1. Stop-loss: $95.19.
Thin upside margin: 5.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5).
ICON plc trades at a P/E of 15.3 (forward 10.1). TrendMatrix value score: 7.9/10. Verdict: Buy (Wait for Entry).
23 analysts cover ICLR with a consensus score of 3.7/5. Average price target: $133.
What does ICON plc do?ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization...
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.